Your browser doesn't support javascript.
Multiple early factors anticipate post-acute COVID-19 sequelae.
Su, Yapeng; Yuan, Dan; Chen, Daniel G; Ng, Rachel H; Wang, Kai; Choi, Jongchan; Li, Sarah; Hong, Sunga; Zhang, Rongyu; Xie, Jingyi; Kornilov, Sergey A; Scherler, Kelsey; Pavlovitch-Bedzyk, Ana Jimena; Dong, Shen; Lausted, Christopher; Lee, Inyoul; Fallen, Shannon; Dai, Chengzhen L; Baloni, Priyanka; Smith, Brett; Duvvuri, Venkata R; Anderson, Kristin G; Li, Jing; Yang, Fan; Duncombe, Caroline J; McCulloch, Denise J; Rostomily, Clifford; Troisch, Pamela; Zhou, Jing; Mackay, Sean; DeGottardi, Quinn; May, Damon H; Taniguchi, Ruth; Gittelman, Rachel M; Klinger, Mark; Snyder, Thomas M; Roper, Ryan; Wojciechowska, Gladys; Murray, Kim; Edmark, Rick; Evans, Simon; Jones, Lesley; Zhou, Yong; Rowen, Lee; Liu, Rachel; Chour, William; Algren, Heather A; Berrington, William R; Wallick, Julie A; Cochran, Rebecca A.
  • Su Y; Institute for Systems Biology, Seattle, WA 98109, USA; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA; Clinical Research Division, Program in Immunology, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA. Electronic address: suyap
  • Yuan D; Institute for Systems Biology, Seattle, WA 98109, USA; Department of Bioengineering, University of Washington, Seattle, WA 98105, USA.
  • Chen DG; Institute for Systems Biology, Seattle, WA 98109, USA; Department of Microbiology and Department of Informatics, University of Washington, Seattle, WA 98195, USA.
  • Ng RH; Institute for Systems Biology, Seattle, WA 98109, USA; Department of Bioengineering, University of Washington, Seattle, WA 98105, USA.
  • Wang K; Institute for Systems Biology, Seattle, WA 98109, USA.
  • Choi J; Institute for Systems Biology, Seattle, WA 98109, USA.
  • Li S; Institute for Systems Biology, Seattle, WA 98109, USA.
  • Hong S; Institute for Systems Biology, Seattle, WA 98109, USA.
  • Zhang R; Institute for Systems Biology, Seattle, WA 98109, USA; Department of Bioengineering, University of Washington, Seattle, WA 98105, USA.
  • Xie J; Institute for Systems Biology, Seattle, WA 98109, USA; Molecular Engineering & Sciences Institute, University of Washington, Seattle, WA 98105, USA.
  • Kornilov SA; Institute for Systems Biology, Seattle, WA 98109, USA.
  • Scherler K; Institute for Systems Biology, Seattle, WA 98109, USA.
  • Pavlovitch-Bedzyk AJ; Institute for Immunity, Transplantation and Infection, Stanford University School of Medicine, Stanford, CA 94305, USA.
  • Dong S; Diabetes Center, University of California, San Francisco, San Francisco, CA 94143, USA.
  • Lausted C; Institute for Systems Biology, Seattle, WA 98109, USA.
  • Lee I; Institute for Systems Biology, Seattle, WA 98109, USA.
  • Fallen S; Institute for Systems Biology, Seattle, WA 98109, USA.
  • Dai CL; Institute for Systems Biology, Seattle, WA 98109, USA.
  • Baloni P; Institute for Systems Biology, Seattle, WA 98109, USA.
  • Smith B; Institute for Systems Biology, Seattle, WA 98109, USA.
  • Duvvuri VR; Institute for Systems Biology, Seattle, WA 98109, USA.
  • Anderson KG; Clinical Research Division, Program in Immunology, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA; Departments of Immunology and Medicine, University of Washington, Seattle, WA 98109, USA.
  • Li J; Institute for Immunity, Transplantation and Infection, Stanford University School of Medicine, Stanford, CA 94305, USA.
  • Yang F; Department of Pathology, Stanford University, Stanford, CA 94304, USA.
  • Duncombe CJ; Division of Global Health, University of Washington, Seattle, WA 98105, USA.
  • McCulloch DJ; Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, WA 98109, USA.
  • Rostomily C; Institute for Systems Biology, Seattle, WA 98109, USA.
  • Troisch P; Institute for Systems Biology, Seattle, WA 98109, USA.
  • Zhou J; Isoplexis Corporation, Branford, CT 06405, USA.
  • Mackay S; Isoplexis Corporation, Branford, CT 06405, USA.
  • DeGottardi Q; Adaptive Biotechnologies, Seattle, WA 98109, USA.
  • May DH; Adaptive Biotechnologies, Seattle, WA 98109, USA.
  • Taniguchi R; Adaptive Biotechnologies, Seattle, WA 98109, USA.
  • Gittelman RM; Adaptive Biotechnologies, Seattle, WA 98109, USA.
  • Klinger M; Adaptive Biotechnologies, Seattle, WA 98109, USA.
  • Snyder TM; Adaptive Biotechnologies, Seattle, WA 98109, USA.
  • Roper R; Institute for Systems Biology, Seattle, WA 98109, USA.
  • Wojciechowska G; Institute for Systems Biology, Seattle, WA 98109, USA; Medical University of Bialystok, Bialystok 15089, Poland.
  • Murray K; Institute for Systems Biology, Seattle, WA 98109, USA.
  • Edmark R; Institute for Systems Biology, Seattle, WA 98109, USA.
  • Evans S; Institute for Systems Biology, Seattle, WA 98109, USA.
  • Jones L; Institute for Systems Biology, Seattle, WA 98109, USA.
  • Zhou Y; Institute for Systems Biology, Seattle, WA 98109, USA.
  • Rowen L; Institute for Systems Biology, Seattle, WA 98109, USA.
  • Liu R; Institute for Systems Biology, Seattle, WA 98109, USA.
  • Chour W; Institute for Systems Biology, Seattle, WA 98109, USA.
  • Algren HA; Swedish Center for Research and Innovation, Swedish Medical Center, Seattle, WA 98109, USA; Providence St. Joseph Health, Renton, WA 98057, USA.
  • Berrington WR; Swedish Center for Research and Innovation, Swedish Medical Center, Seattle, WA 98109, USA; Providence St. Joseph Health, Renton, WA 98057, USA.
  • Wallick JA; Swedish Center for Research and Innovation, Swedish Medical Center, Seattle, WA 98109, USA; Providence St. Joseph Health, Renton, WA 98057, USA.
  • Cochran RA; Swedish Center for Research and Innovation, Swedish Medical Center, Seattle, WA 98109, USA; Providence St. Joseph Health, Renton, WA 98057, USA.
Cell ; 185(5): 881-895.e20, 2022 03 03.
Article in English | MEDLINE | ID: covidwho-1649960
ABSTRACT
Post-acute sequelae of COVID-19 (PASC) represent an emerging global crisis. However, quantifiable risk factors for PASC and their biological associations are poorly resolved. We executed a deep multi-omic, longitudinal investigation of 309 COVID-19 patients from initial diagnosis to convalescence (2-3 months later), integrated with clinical data and patient-reported symptoms. We resolved four PASC-anticipating risk factors at the time of initial COVID-19 diagnosis type 2 diabetes, SARS-CoV-2 RNAemia, Epstein-Barr virus viremia, and specific auto-antibodies. In patients with gastrointestinal PASC, SARS-CoV-2-specific and CMV-specific CD8+ T cells exhibited unique dynamics during recovery from COVID-19. Analysis of symptom-associated immunological signatures revealed coordinated immunity polarization into four endotypes, exhibiting divergent acute severity and PASC. We find that immunological associations between PASC factors diminish over time, leading to distinct convalescent immune states. Detectability of most PASC factors at COVID-19 diagnosis emphasizes the importance of early disease measurements for understanding emergent chronic conditions and suggests PASC treatment strategies.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Convalescence / COVID-19 Type of study: Cohort study / Diagnostic study / Observational study / Prognostic study Topics: Long Covid Limits: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged / Young adult Language: English Journal: Cell Year: 2022 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Convalescence / COVID-19 Type of study: Cohort study / Diagnostic study / Observational study / Prognostic study Topics: Long Covid Limits: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged / Young adult Language: English Journal: Cell Year: 2022 Document Type: Article